CPNE1 Is a Useful Prognostic Marker and Is Associated with TNF Receptor-Associated Factor 2 (TRAF2) Expression in...

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Copine 1 (CPNE1) regulates cell differentiation, but its role in prostate cancer remains unclear.
• Investigating CPNE1's clinical and biological significance is crucial for understanding prostate cancer progression.

Purpose of the Study:

• To determine the clinicopathological value of CPNE1 in prostate cancer.
• To explore the association between CPNE1 and TRAF2 expression in prostate cancer patients.
• To evaluate CPNE1 as a prognostic marker for recurrence-free survival.

Main Methods:

• Analysis of Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) datasets for CPNE1 expression.
• Immunohistochemistry on prostate tissue samples.
• Kaplan-Meier curves, log-rank tests, and Cox regression for survival analysis.
• Western blotting and immunofluorescence to assess CPNE1's effect on TRAF2 in DU-145 cells.

Main Results:

• CPNE1 expression is significantly higher in prostate cancer tissues than normal tissues (P=0.006).
• CPNE1 is upregulated in castration-resistant prostate cancer (P<0.001).
• High CPNE1 expression correlates with advanced tumor stage, higher Gleason score, and poorer recurrence-free survival.
• CPNE1 positively associates with TRAF2 expression, and CPNE1 overexpression upregulates TRAF2 in prostate cancer cells.

Conclusions:

• CPNE1 serves as a valuable prognostic marker for prostate cancer recurrence-free survival.
• CPNE1 expression is positively related to TRAF2 expression in prostate cancer.
• These findings highlight CPNE1's potential role in prostate cancer progression and as a therapeutic target.